Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2Recruiting 2Completed 2Withdrawn 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Non-Small-Cell Lung 3Melanoma 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Liposarcoma 1Leiomyosarcoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 28Radiotherapy 20pembrolizumab 9Paclitaxel 9Surveys and Questionnaires 8Cetuximab 8Fluorouracil 7Docetaxel 7Radiotherapy, Intensity-Modulated 6Carboplatin 6apatinib 5Low-Level Light Therapy 5Blood Specimen Collection 5durvalumab 4Standard of Care 4Magnetic Resonance Imaging 4Gemcitabine 4Cyclophosphamide 4Celecoxib 4Tegafur 3Radiation 3Oncolytic Virotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lidocaine 3Immunoenzyme Techniques 3Drug Therapy 3Chemotherapy, Adjuvant 3Biopsy 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Head and Neck Neoplasms × cemiplimab × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04460456 2022-06-30

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Silverback Therapeutics

Phase 1 Unknown
58 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡